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Cancer stem cells (CSCs) have been identified in hematopoietic and solid tumors. However, their precursors—namely,
precancerous stem cells (pCSCs) —have not been characterized. Here we experimentally define the pCSCs that have the
potential for both benign and malignant differentiation, depending on environmental cues. While clonal pCSCs can develop
into various types of tissue cells in immunocompetent mice without developing into cancer, they often develop, however, into
leukemic or solid cancers composed of various types of cancer cells in immunodeficient mice. The progress of the pCSCs to
cancers is associated with the up-regulation of c-kit and Sca-1, as well as with lineage markers. Mechanistically, the pCSCs are
regulated by the PIWI/AGO family gene called piwil2. Our results provide clear evidence that a single clone of pCSCs has the
potential for both benign and malignant differentiation, depending on the environmental cues. We anticipate pCSCs to be
a novel target for the early detection, prevention, and therapy of cancers.
Citation: Chen L, Shen R, Ye Y, Pu X-A, Liu X, et al (2007) Precancerous Stem Cells Have the Potential for both Benign and Malignant
Differentiation. PLoS ONE 2(3): e293. doi:10.1371/journal.pone.0000293
INTRODUCTION
A variety of cancers can arise from reversible premalignant stages
of hyperplasia and dysplasia, which might progress to primary and
invasive tumors. Recent evidence indicates that the process is
initiated by the cancer stem cells (CSCs) [1–3]. While CSCs have
been identified in the hematopoietic and solid cancers [4–9], the
mechanisms underlying CSC derivation are largely unknown.
CSCs may originate from a stem or progenitor cell through
a precancerous stage, during which stem cells are hierarchically
disturbed in their genetic program of self-renewal by environ-
mental insults [1,6,10], whereas the progenitor cells may acquire
the properties of stem cells [11]. Thus, whether or not pCSCs exist
and how they develop into cancer cells are critical issues for cancer
stem cell biology.
While investigating tumor incidence in mice with the targeted
mutation of p53 and stat-1 genes [12,13], we found that a mouse
developed dendritic cell (DC)-like leukemia, which was character-
ized by massive infiltration of CD11c
+CD8a
+ DCs in spleen,
lymph nodes, and liver [14]. After cloning DC-like lines from the
spleen of this leukemic mouse [14], 3 of 25 clones (designated as
2C4, 3B5C and 3B6C) expressed neither hematopoietic and
lineage (Lin) markers nor hematopoietic stem cell (HSC) markers
(CD45
2c-kit
2Sca-1
2Lin
2). These cells have the potential for both
benign and malignant differentiation, and their fate appears to be
determined by environmental cues. Since they have the properties
of both normal stem cells and CSCs, we use the term pCSCs to
recognize their hybrid-like characteristics. The progression of
pCSCs to cancer cells is associated with up-regulation of c-kit and
Sca-1, as well as with lineage markers. Mechanistically, their
expansion is regulated by a PIWI/AGO gene piwil2 (alias mili in
mouse and hili in human) [15,16]. These findings will help us
develop a novel strategy for the early detection, prevention, and
treatment of cancers.
RESULTS
1. pCSCs exhibit stem-like cell phenotype
Although cancer stem-like cells can be detected in the existing
tumor cell lines [17], no clonal CSC lines have been established.
We previously reported that we cloned DC-like cell lines from the
spleen of a leukemic mouse [14]. Here, we found that 3 of the 25
clones (2C4, 3B5C and 3B6C) failed to express hematopoietic pan-
marker CD45 and lineage (Lin) markers CD3e, CD4, CD8, B220,
Ter-119, CD11b and Gr-1 (Fig. 1a), while the remaining clones,
such as 3B11, exhibited monocytic and B cell phenotypes, expres-
sing CD45, CD11b, B220, and CD19 (Fig. 1b). Further analysis
of the stem cell-related markers revealed a unique phenotype–
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PLoS ONE | www.plosone.org 1 March 2007 | Issue 3 | e293Figure 1. Phenotypical and cytological characterization of pCSCs. A & B, The phenotype of pCSC clones (A) and monocytic cell clones (B) from the
same mouse (14): the data shown are a representative of pCSC (2C4; A) and monocytic clones (3B11; B). The phenotype of the 2C4 clone was similar
to 3B5C and 3B6C clones (not shown). Red histograms represent isotype mAbs (A & B), and black (A) or green (B) histograms represent specific mAbs.
C, Phase contrast micrographs: a representative (2C4) of 3 pCSC clones (top panel) and differentiated DC-like clone (3B11) from the same mouse
(bottom panel; original magnification 6200). D, Comparison of cytology between the pCSCs, 3B11, and HSCs: HSC-enriched CD34
2Lin
2 and
CD34
+Lin
2 cells were sorted by FACSorter from the BM of B6 mice (Wright-Giemsa staining; original magnification61000). DC-like cell line 3B11 was
derived from the same mouse of the pCSCs. E, The karyotype of pCSCs: a representative of 2C4 clone that exhibits a pseudodiploid karyotype with
multiple chromosomal translocations identical to the 3B5C and 3B6C clones (not shown). Left panel: karyotype of the 2C4 clone; right panel: an
example of Robertsonian translocations in the 3B11 clone.
doi:10.1371/journal.pone.0000293.g001
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high (Fig. 1a)– somewhat distinct from normal hematopoietic
stem/progenitor cells reported previously [18] and the 3B11 clone
shown in Fig. 1b. Cytological analysis demonstrated that all the
clones exhibited blast-like cell morphology with large numbers of
cytoplasmic vacuoles or granules. This morphology was distinct
from the DC clones, such as the 3B11 clone of the same mouse
[14], but comparable to the normal BM-derived CD34
+Lin
2 and
CD34
2Lin
2 blast cells (Fig. 1c & d). Overall, these clones exhibit
a stem-like cell phenotype CD45
2c-kit
2Sca-1
2Lin
2CD44
high
(CD45KSL
2CD44
high). Cytogenetic analysis revealed that all the
three clones carried an identical pseudodiploid karyotype with
multiple chromosomal translocations. There are 40 chromosomes,
and a sex chromosome (X or Y) is missing (Fig. 1e). In contrast,
DC-like cells 3B11 from the same mouse are hyperdiploid with
46,54 chromosomes and marked by karyotypic instability and
several abnormal metacentric and submetacentric chromosomes,
frequently resulting from Robertsonian translocations (Fig. 1e).
These metacentric and submetacentric chromosomes varied from
cell to cell. None of the cells were identical because of the marked
karyotypic instability. Overall, the pCSCs exhibited a phenotype
of CD45
2c-kit
2Sca-1
2Lin
2CD44
high or CD45KSL
2CD44
high
with multiple cytogenetic alterations. They are phenotypically
and cytogenetically distinct from the differentiated cancer cells in
the same host.
2. pCSCs have incompletely abolished multipotency
To test whether the pCSCs have the activity of hematopoietic
progenitors, we evaluated the multipotency of pCSCs using the
colony-forming cell (CFC) assay [19]. About 30,50% of the input
cells had colony-forming activity (CFU) in the medium of
Methocult GF M3434 (Figure S1a). Although we did not observe
all types of CFUs that may be differentiated from normal HSCs,
such as burst forming units-erythroid (BFU-E), CFU-M (macro-
phage), and CFU-G (granulocyte), three types of CFUs were
identified from these clones, including CFU-E (erythroid), CFU-
mix, and CFU-GM (Fig. S1b). Accordingly, early lineage
differentiation markers hemoglobin Hbb-1 for erythrocytes,
CD41 for megakaryocytes [20], and c-fms for granulocytes/
macrophage [21] were either constitutively expressed (i.e. CD41)
or up-regulated (i.e. Hbb1 and c-fms), as demonstrated by RT-
PCR (Fig. S1c). Conversely, erythropoietin receptor (EpoR) [22],
von Willebrand factor (vWF) [23], and granulocyte colony
stimulating factor receptor (G-CSFR), which are differentiation
markers for the late stages of, respectively, erythrocytes, mega-
karyocytes and granulocytes/monocytes/macrophages, were un-
detectable in all the clones of pCSCs (Fig. S1c). These results
suggest that the normal development program of the pCSCs was
dramatically impaired, but not completely abolished.
To confirm our results, we cultured the pCSCs in suspension
medium in the presence of myeloid or lymphoid lineage-specific
cytokines. In the presence of G-CSF [24], all the pCSCs clones
proliferated, and the cumulative cell number increased until the
differentiated myeloid cells were morphologically identified (Fig.
S2b; between d9 and d13). Then, the cell numbers progressively
decreased, and almost all the cells died within 3 wks of culture
(Fig. S2a, b, and data not shown). Because the cultures were split
at the log phase in an attempt to prevent cell death caused by
overgrowth, the cell death appeared to be associated with their
inability to complete the differentiating program, even though
some of the cells had acquired the ability to phagocytose apoptotic
cells (Fig. S2b, d17). In addition, GM-CSF also induced cell death.
For example, 2C4 cells died at day 6,7 of culture while in the
presence of recombinant murine GM-CSF (Fig. S2c). This sug-
gests that it was the GM-CSF-mediated differentiating program,
not the G-CSF-mediated one, which led to their earlier death.
Moreover, the pCSCs also have the potential to differentiate into
lymphoid cells when co-cultured with IL-7 and/or IL-15. This was
shown when lymphoid markers B220 and NK1.1 were up-
regulated on the pCSCs, albeit the markers were expressed
variably (Fig. S2d). However, they also failed to complete the
differentiating program and underwent apoptosis within two wks
of culture (Fig. S2e, d12). In contrast, 3B11 cells did not die when
cultured in the presence of G-CSF (data not shown). Taken
together, the results suggest that the pCSCs retain incomplete
potency of differentiation toward various hematopoietic lineages.
3. pCSCs have long-term repopulating activity
The aborted in vitro hematopoietic differentiation may indicate
how strict environmental cues influence pCSC differentiation
and/or survival. To test this hypothesis, a competitive in vivo
repopulating assay was performed [19]. Lethally irradiated
CD45.1
+ congenic B6 mice were injected i.v. with both 2C4,
3B5C or 3B6C cells and recipient-type bone marrow (BM) cells.
The latter, BM cells were added to the injection to minimize
recipient deaths due to lethal irradiation. Donor-derived CD45.2
+
lymphoid (CD3e
+) and myeloid (CD11b
+ or Gr-1
+) cells in the
peripheral blood were monitored by flow cytometry beginning
,4 wks post-transplant. CD45.2
+ donor cells were not signifi-
cantly detected until ,8 wks after transfer (Fig. 2a). About
0.5,10% more CD45.2
+CD11b
+ and CD45.2
+Gr-1
+ cells were
detected, depending on individual mice or experiments
(5,10 mice/expt) (Fig. 2a). Two weeks later, the pCSC-derived
CD45.2
+ cells decreased unexpectedly to less than 0.5% in the
peripheral blood and were gone at ,13 wks (Fig. 2a). These
results suggest that, like our experiments performed in vitro, the
pCSCs also have multipotent but incomplete differentiation in vivo,
eventually leading to cell apoptosis. The incomplete differentiation
may explain the low myeloid engraftment, as well as the absence of
lymphoid engraftment. We define the process as differentiation-
induced cell death (DICD), probably a protective mechanism that
prevents pCSCs from progressing to malignant cells.
In addition to DICD, the transient in vivo expansion of pCSC-
derived hematopoietic cells in the recipients (Fig. 2a) might be
associated with the pCSC that lacks long-term repopulating
activity. To test this possibility, a neomycin-resistant (neo
r) gene was
used as an indicator of long-term repopulating activity in the
competitive repopulating assay, as described above, because the
pCSCs were derived from a p53
2/2Stat-1
2/2 mouse, which
carried genome-integrated neo
r gene [12,13]. The neo
r gene was
detected in the blood or BM cells of recipients even 10 months
after transplantation by HANDS-Nested DNA-PCR, a technique
that combines HANDS (Homo-Tag Assisted No-Dimer System)
PCR [25,26] with Nested PCR [27] and is used to ensure the
specificity and sensitivity of detection. The neo
r was detected in all
of the recipients, though not in all the tissues examined (Fig. 2b).
The repopulating activity was transferable because the neo
r was
detected in various organs of secondary recipients that received
BM cells from the primary recipients (Fig. 2c). Surprisingly, while
the neo
r gene was undetectable in the BM cells of some primary
recipients (Fig. 2b), it was readily detected in the secondary
recipients receiving these BM cells (Fig. 2c). Thus, the lack of
detectable neo
r in the BM of primary recipients does not show that
pCSCs are unable to repopulate the BM of these recipients; rather,
it reflects the presence of either rare, quiescent pCSCs that
repopulated the BM of primary recipients or an extremely low
frequency of pCSCs resulting from expansion followed by
apoptosis, as shown in Fig. 2a. These results suggest that pCSCs
have the capacity of long-term repopulation.
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nonmalignant cells
The lethally irradiated mice receiving both pCSCs and BM cells
survived tumor-free for up to 10 months, except for 10,20% of
the mice, which died within 10 d after injection, probably due to
an effect of the irradiation. In addition to the BM and blood, neo
r
was also detected in the liver, kidney, small intestine, heart and/or
lungs of both primary (Fig. S3) and secondary recipients (Fig. 2b),
indicating that the pCSCs either distributed in various organs in
a quiescent status or differentiated into tissue-specific cells in these
organs or tissues.
To test these two possibilities, we stably transduced 2C4 cells
with lentiviruses, which carried an enhanced green fluorescent
protein (eGFP) gene, to track the fate of pCSCs in recipients. We
obtained several clones, such as clone 2C4G2 (Fig. S4) that
expressed a high level of eGFP. The 2C4G2 and parent 2C4 cells
were intravenously transplanted, respectively, into lethally irradi-
ated, BM-reconstituted CD45.1 congenic mice, which should
provide stem cells with a vigorously regenerative environmental
cue. The donor-derived eGFP
+ cells, albeit lower in frequency,
were readily detected in various organs, such as the spleen, liver,
kidney, small intestine, or adipose tissues, of all the mice that had
received 2C4G2, but not 2C4 cells, for 5 months (Fig. 3a and data
not shown). Some eGFP
+ cells exhibited the morphology of tissue
origin, including endothelial cells, tubular epithelial cells, Kupffer’s
cells, histiocytes, macrophages/monocytes, and hepatoid cells
(Fig. 3a). In the liver, eGFP
+ Kupffer’s cells and hepatoid cells
were usually found in the regenerative areas (Fig. 3a). Interestingly,
none of the observed eGFP
+ cells exhibited significant dysplastic
changes (Fig. 3a). The results suggest that while the pCSCs were
generally unable to completely differentiate into mature hemato-
poietic cells in vitro (Fig. S1 & S2); some of them may differentiate
into tissue-specific cells in a regenerative environment. Interest-
ingly, none of the recipients developed tumors under the
conditions.
To confirm the importance of environmental cues for the
differentiation of pCSCs, we investigated their fates during embryo
Figure 2. pCSCs have long-term repopulating activity. Congenic CD45.1 B6 mice were lethally irradiated and injected i.v. with 0.5,1610
6 2C4, 3B5C
or 3B6C cells along with 2,5610
5 recipient-type BM cells. Donor-specific CD45.2
+ lymphoid (CD3e
+) and myeloid (CD11b
+ or Gr-1
+) cells were
monitored by flow cytometric analysis of blood cells starting from 4 wks post transfer, once every two wks, until 18 wks (A). The mice were sacrificed
10 moths post transfer, and the blood and BM cells were collected for HANDS-Nested DNA PCR to identify donor-derived cells (B). To verify the self-
renewal capability of the long-term repopulated donor cells, 1610
6 BM cells from the primary recipients were injected i.v. into the secondary
recipients, which were sacrificed 10 wks post transfer. The pCSC-derived neo
r gene in the BM, liver, and spleen was determined by HANDS-Nested
DNA PCR (C). The data shown in B are from a recipient with transient expansion of pCSC-derived hematopoietic cells at 8 and 13 wks post transfer,
and the data shown in C & D are from one of 3 experiments (5,10 mice/group/expt).
doi:10.1371/journal.pone.0000293.g002
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PLoS ONE | www.plosone.org 4 March 2007 | Issue 3 | e293Figure 3. pCSCs can differentiate into various type of tissue cells. A, Differentiation of pCSCs into hematopoietic and non-hematopoietic cells: The
lethally irradiated CD45.1 congenic B6 mice were injected i.v. with 1610
6 2C4 (n=5) or eGFP
+ 2C4G2 cells (n=10), along with 5610
5 recipient-type
BM cells, as described above. The mice were sacrificed 5 months post transfer. Various organs, including the liver, kidney, spleen and adipose tissues
were harvested, fixed in 10% formaldehyde of PBS, prepared for H & E. staining, and examined under fluorescent microscope. At least three
discontinuous sections (100 mm/step) were examined for each organ to ensure that eGFP
+ cells were identified under the fluorescent microscope.
The morphology of eGFP
+ cells was determined under the bright field of the fluorescent microscope (original magnification 61000). B–E,
Development of pCSCs in blastocyst chimeric mice: E3.5 dpc of FVB mice were injected with 2C4G2 (8,10 cells per blastocyst) and transferred to
pseudopregnant surrogate mothers. The progeny were delivered and grew to adult without any complication. The data shown are from one of two
experiments in which 8 progeny (male: n=6; female: n=2) were obtained. One male mouse died of fighting at 3 months of age. B, eGFP
+ RBCs in 7/8
of the chimeric mice: The data represent the air-dried blood smears from two mice, at the age of 2 months, examined under, respectively, the bright
and fluorescent fields of a fluorescent microscope (Nike, E400, Japan). C, pCSC-derived eGFP
+CD45
+ cells: peripheral blood was harvested from the
chimeric mice at age 2 months (n=6; other two pregnant mice were not examined) or control FVB mice (n=10), stained with PE-conjugated mAb to
CD45, and analyzed by flow cytometry. D&E ,Living image of the chimeric mice: A representative living image of the chimeric mice at 4 months of
age is shown in D, demonstrated by IVIS imaging systems incorporated with Living ImagingH software (Xenogen Inc.); and the eGFP-derived photon
counts in the region of interest (ROI) of 7 mice are shown in E. Normal FVB mice were used as control for living imaging.
doi:10.1371/journal.pone.0000293.g003
Precancerous Stem Cells
PLoS ONE | www.plosone.org 5 March 2007 | Issue 3 | e293development using a blastocyst complementary assay, in which
abnormal genetic programs may be corrected [28]. 2C4G2 or 2C4
cells were injected into 3.5 d old murine blastocysts (,8 cells per
blastocyst). The chimeric progeny were delivered from foster
mothers and grew to healthy adults. As shown in Fig. 3b, eGFP
+
red blood cells (RBCs) were detected in the peripheral blood of
88% (7/8) of the 2C4G2 chimeric mice, although their
morphology was subnormal compared to the host RBCs, and
the eGFP protein was variably expressed. The number of eGFP
+
RBC was ,50 in each slide of blood smears. About 0.5% of the
gated white blood cells (WBCs) expressed both eGFP and CD45,
as revealed by flow cytometry (Fig. 3c). Consistently eGFP signals
were also detected in all 2C4G2 chimeric mice by IVIS
TM
imaging systems (Xenogen Inc.) (Fig. 3d & e). The results suggest
that the pCSCs bypassed the checkpoint of differentiation-induced
cell death, developed ‘‘normally’’ in the blastocysts, and
differentiated into RBCs and WBCs in the chimera mice despite
of low frequency. Importantly, the chimeric mice did not develop
tumors within 20 months of follow up. The results indicate that the
embryonic (juvenile) environment can support ‘‘benign’’ de-
velopment of pCSCs, probably through correcting an altered
oncogenic genetic program.
Taken together, we propose that pCSCs have the potential to
differentiate into various types of nonmalignant tissue cells within
appropriate environmental cues.
5. pCSCs develop into cancers in immunodeficient
but not in immunocompetent mice
While pCSCs were detected in the lethally irradiated, BM
reconstituted mice (Fig. 2a–c & 3a) and blastocyst chimeras
(Fig. 3b–e), they developed into neither leukemic nor solid tumors
after i.v. injection, despite that they were immortalized in vitro.
This may be due to the immune surveillance system [29], which
eliminated the pCSCs when they were progressing to CSCs or
cancer cells, or possibly due to the route of cell delivery. The route
of injection can dictate the environmental conditions, which effects
the developmental fate of pCSCs.
To test this hypothesis, pCSCs were injected s.c., i.p. or i.v. into
severe combined immune deficient (SCID) mice, BM reconsti-
tuted, or naive B6 mice; conditions which may provide different
levels of immune surveillance (see discussion). The results
demonstrated that both the surveillance system and the injection
route had an impact on pCSC development in recipients; they
developed into either solid or leukemic tumors in immunodeficient
mice (Supplementary Table S1). 2C4, 2C4G2 and 3B5C cells, but
not 3B6C cells, developed into solid tumors at the site of injection,
regardless of i.p. or s.c. inoculation. The latency, incidence, and
growth kinetics of tumors were also variable with the experiments
(Fig. 4a &b). For example, the tumors were palpable, respectively,
at days 10 and 21 post inoculation in the expt 1 and expt 2
(Fig. 4b). In most of the experiments, once tumors were palpable,
the tumor growth curves rose steeply, and the mice had to be
sacrificed within one wk (Fig. 4b). Consistent with the properties of
tumorigenic cancer cells [5], pCSC-derived tumors grew much
faster than 3B11 cell-derived tumors (Fig. 4c).
Some large tumors showed gelatinous areas with sharply
delineated regions of tan-pink and gray (Fig. 4d), suggesting that
the composition of the tumors was heterogeneous. Consistent with
their gross appearance, the tumors were composed of various types
of cancer cells, such as lymphoid, sarcomatoid (spindle) and
histiocytic cancer cells (Fig. 4e).
Although 3B6C cells did not develop into a solid tumor in situ,
they infiltrated the spleens of about 80% of recipient mice,
resembling chronic leukemic alterations (Fig. 4a & f). Large
numbers of atypical neutrophils or eosinophils were observed in
the spleen (Fig. 4f), suggesting that 3B6C cells were distinct from
2C4 and 3B5C clones with regard to the resultant tumor type,
although the karyotype between them were identical (Fig. 1e and
not shown). The results indicate that pCSCs from a single clone
can differentiate into various types of cancer cells.
In addition, metastatic cancers were detected in the spleen,
liver, prostate, pancreas, and brain, but not the lungs (Fig. S5 and
not shown). Some of them demonstrated spindle/oval cell
morphology (Fig. S5). Interestingly, benign differentiation of
pCSCs in the liver with metastatic cancer was also observed in
the regenerative area of liver parenchyma, which was revealed by
the scattered neomycin-positive hepatoid cells (Fig. 4g), suggesting
that the benign and malignant differentiations of pCSCs are
delicately regulated by microenvironments.
The i.v. injected pCSCs, interestingly, did not develop into
tumors in the solid organs of SCID mice, even at 5 months post
injection (Supplementary Table S1). However, chronic leukemic
alterations were observed in the spleens of all the mice injected
with 2C4, 3B5C or 3B6C clones (Fig. S6b). Fewer pCSC-like cells
were detected in the peripheral blood (Fig. S6c). Moreover, all the
organs examined, including the liver, kidney, lungs, small intestine
and pancreas were histologically normal (data not shown). In
contrast, no leukemic alterations were observed in the spleens of
either the naive or BM-reconstituted immunocompetent B6 mice,
which were injected i.v. with 2C4, 3B5C or 3B6C cells (Fig. S6d;
Supplementary Table S1). Taken together, the results suggest
several important points for the tumorigenesis of the pCSCs. First,
the pCSCs require an appropriate environmental cue, such as
tissue extracellular matrix [30], to acquire tumorigenicity. This
may explain why the pCSCs can develop into solid tumors only
when injected s.c. or i.p., but not i.v. Second, the immune system
may suppress pCSCs progressing to cancer cells because they did
not develop into tumors when injected into immunocompetent
mice. Finally, the pCSCs may represent an early developmental
stage of CSCs, namely precancerous stage; depending on the
environmental cues. They may undergo either benign or
malignant differentiation or remain quiescent.
6. Phenotypic and genetic alterations when pCSCs
progress to cancer
If the pCSCs are at an early stage of cancer development, we
should observe the phenotypic and genetic changes as they
become cancerous. To verify the hypothesis, we analyzed 2C4 and
2C4G2 cell-derived lymphomas. As shown in Fig. 5A, CD45
+Lin
+
and CD45
2Lin
+ tumor cells were detected in both tumors. These
cells developed from the injected pCSCs because both populations
expressed eGFP in the 2C4G2-, but not in the 2C4-derived
tumors. Interestingly, eGFP was somewhat down-regulated when
the pCSCs differentiated into Lin
+ cells (Fig. 5A). Further analysis
of the tumor cells revealed that after 2 days of culture,
CD45
+eGFP
low or + (p1, 2 & 3) and CD45
2eGFP
low populations
(p4) abnormally expressed all the lineage markers (CD3e, CD11b,
B220, Ter-119 and Gr-1) with variable levels. Other lineage
markers, such as NK1.1, were also expressed when CD45 was up-
regulated (Fig. 5b: p1, 2 & 3). Importantly, the up-regulation of
CD45 and lineage markers was accompanied by the expression of
c-kit (CD117) (Fig. 5b: p1,4) and Sca-1 (Fig. 5b: p1,3). The
expression of CD117 and Sca-1 may signify the malignancy of the
Lin
+ cells, because CD117, a transmembrane tyrosine kinase
receptor encoded by proto-oncogene c-kit, and Sca-1, a glycosyl-
phosphatiylinositol-linked cell surface protein, have been identified
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PLoS ONE | www.plosone.org 6 March 2007 | Issue 3 | e293Figure 4. pCSCs developed into various type of tumors in immunodeficient mice. A, Tumor incidence from 3 experiments. Equal numbers of sex
matched SCID mice were injected s.c. or i.p. with 5610
6 pCSCs. No significant difference in incidence was observed between s.c. and i.p. injected
mice. As a control, C57BL/6 mice injected s.c. (n=10) or i.p. (n=10) with 2C4 cells did not develop tumors within 5 months of observation (data not
shown) ‘‘*’’ indicates that a mouse developed ascites, ‘‘**’’ indicates that the 3B6C cells infiltrated in the liver and spleen (see E). B, Kinetics of tumor
growth: the data shown are from experiments 1 & 2 in A. Each color in B corresponds to a specific cell line. C, Comparison of tumorigenesis between
pCSCs (2C4) and differentiated cancer cells (3B11); (n=10/group, each group includes 5 males and 5 females). D, A representative of gross tumors
from a mouse injected i.p. with 3B5C clone. E, A histological representative of pCSC-derived tumors from the mice injected i.p. with 2C4 or 3B5C
clones. F, A histological representative from the spleen of mice injected i.p. or s.c. with 3B6C clone. Note that megakaryocytes in the spleen of normal
SCID mice were replaced by atypical neutrophils or eosinophils. G, Benign differentiation of pCSCs in the liver with metastatic cancers: (a) H & E
staining of a liver section with metastatic cancers from a mouse injected i.p. with 2C4 cells (original magnification: 6200). (b) Immunohistochemical
staining of the liver section from the same mouse with antibody to neomycin, showing neomycin
+ cancer cells (original magnification: 6400). (c)
Immunohistochemical staining of pCSC-derived hepatoid cells in the regenerative area of the liver sections from the same mouse (original
magnification: 6200). (d) The enlarged micrographs of hepatoid cells demonstrated in (c).
doi:10.1371/journal.pone.0000293.g004
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33]. Based on the results (Fig. 5a & b), we propose a road map for
the pCSCs progressing to cancer cells: CD45
2c-kit
2Sca-1
2
Lin
2RCD45
2c-kit
+Sca-1
2Lin
+RCD45
+c-Kit
+Sca-1
+Lin
+.F u r t h e r
characterization of the populations is ongoing in our laboratory.
Based on the genetic model of colorectal tumorigenesis [34], we
assumed that the karyotype of pCSCs might be altered as they
progressed to cancer. To test the hypothesis, we analyzed the
karyotypes of pCSC-derived tumors. Although the karyotypes of
the tumor cells were the same as the parental pCSCs (Fig. 1e), we
found a few changes. Compared to the parental line karyotype, for
example, one 2C4-derived tumor cell line exhibited a deleted 10
and an add [14] in 90.6% (29/32) of the cells, while the other 3
cells had the dup [14] and a third copy of the del [15] found in the
pCSCs, thus showing karyotypic evolution in both clones of this
line compared with the parental line. Thus, genetic alteration was
dynamic when pCSCs were progressing to cancer.
7. The ectopically expressed piwil2 gene regulates
pCSC expansion in vitro
Since the pCSCs exhibited the properties of stem cells, as well as
the potency of tumorigenesis, we examined the expression of
embryonic and adult stemness-related genes in these cells: mili (a
mouse homologous of piwil2) [15], Bmi-1 [35], Notch-1 [36],
Endoglin [37], ABCG-2 [38], POUF1/Oct-4 [39], Nanog [39],
TDGF1/Cripto [40], Zfp42/REX1 [41], Fzd2 [42], Fzd5 [43], b-
catenin [44], Smo [45], c-Myc [46], Flt3 [47], Bcl-2 [48] and Stat-3
[49]. Some of these genes are also associated with tumor
development [50]. BM-derived CD34
+Lin
2 and CD34
2Lin
2
cells, which were enriched with hematopoietic stem cells (HSCs),
were used for comparison. As shown in Fig. 6a, both embryonic
and adult stem cell-related genes were detected in the pCSCs,
except for Nanog and ABCG-2. Adult stem cell- and tumorigenesis-
related genes, such as Bmi-1, Notch-1, Fzd2, Fzd5, Flt3, Smo, b-
catenin, Stat-3, and Bcl-2 were detected in both pCSCs and normal
stem cells (NSCs). Interestingly, embryonic stem cell-related genes,
including Pouf1/Otc4, TDGF1, Zfp42/REX1 and Mili (piwil2),
whose homologue has a conserved function in stem cell division
[16], were exclusively expressed in pCSCs. Among them, only mili
was stably expressed in all the clones of pCSCs; in contrast, miwi
[15], a member of mouse PIWI/AGO gene family, was not detect-
able in these pCSCs (Fig. 6a), although its human homologue hiwi
was detected in human CD34
+ HSCs [51]. The unique pattern of
mili and miwi mRNA in pCSCs does not seem to be associated with
the deficiency of p53 and Stat-1, because we could not detect
either gene in the p53-null embryonic fibroblasts or the Stat-1-null
hematopoietic cells (data not shown). The results suggest that mili
may play an important role in pCSC development. Thus, we
further examined the effect of mili on pCSC expansion in vitro.W e
knocked down the mili gene in 2C4 cells using mili-specific siRNA,
resulting in a significant decrease of 2C4 cell expansion (Fig. 6b &
c). The results suggest that mili promotes pCSC proliferation,
which is consistent with the recent observations for the mili-
overexpressing NIH3T3 cell line [52].
To confirm this idea, we transduced murine BM cells with
Lenti-GFP-Mili or Lenti-GFP pseudoviruses (Fig. 7a) in the
XLCM-conditioned medium [53]. After 10 days of transduction,
a number of eGFP
+ colonies were observed in the cultures of BM
cells transduced with Lenti-GFP-Mili, whereas considerably fewer
eGFP
+ colonies were demonstrated in the control cultures, despite
the comparable efficiency of transduction (Fig. 7b & c).
Interestingly, some embryonic body (EB)-like colonies were
observed in the cultures of mili-transduced BM cells (Fig. 7c).
The results verify that ectopic expression of mili promoted cell
proliferation. Thus, it is likely that ectopic expression of mili may
contribute to the development of pCSCs. However, mili was not
required for the self-renew of normal hematopoietic stem cells
(HSCs), because the number and repopulation activity of the
HSCs from the BM of mili-disrupted mice was not affected [15].
DISCUSSION
Though cancer can arise from a stem-like cell, namely CSC, little
is known about the mechanisms for CSC development. Extensive
investigations have revealed that human tumorigenesis is a com-
plex, multistep process often requiring a concordant expression of
several genes, including multiple genetic and epigenetic alterations
Figure 5. Phenotypic alterations of pCSCs progressing to cancer. Single tumor cells were either prepared and freshly stained with mAb to CD45 and
a mixture of lineage-specific mAbs to CD3, CD11b, Ter-119, Gr-1 and B220 (A) or cultured for 2 d and stained with mAb to CD45 in combination with
mAbs to lineage markers or to c-kit and Sca-1 as indicated (B). The samples were analyzed by three- (A) or four-color flow cytometry (B). The green
and red dot plots or histograms represent, respectively, the tumor cells derived from eGFP
+ 2C4G2 (green) and eGFP
2 2C4 (red) cells (A). Five
populations (p1,5) of tumor cells are identified based on the level of CD45 and eGFP expression (B).
doi:10.1371/journal.pone.0000293.g005
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adhesion molecules and DNA repair genes, genetic instability, as
well as telomerase activation [34,54]. Since stem cells are long-
lived cells, they are the likely subject of accumulating mutations
that lead to their malignant transformation and tumor initiation
[1,10]. Thus, the cells that hierarchically transit from normal stem
cells or committed tissue progenitor cells to CSCs are defined as
precancerous stem cells (pCSCs), which may be uncommitted with
incomplete multipotency. However, they seem to be predeter-
mined, depending on environmental cues, in the formation of solid
or leukemic tumors.
We experimentally defined several stem-like cell clones as
pCSCs because they have the potential for both benign and
malignant differentiation, seemingly reflecting an early stage of
CSC development (Fig. 8). The pCSCs have the characteristics of
a stem-like cell: self-renewal and multipotency of differentiation,
albeit incomplete. The property of benign differentiation can
distinguish them from CSCs, whereas the property of malignant
differentiation can distinguish them from normal stem cells (NSCs)
(Fig. 8a). In other words, pCSCs may represent an intermediate
cell between normal and cancer stem cells if a cancer arises from
a stem cell, or an intermediate cell between committed tissue cells
and CSCs. The latter is likely should cancer arise from
a committed progenitor cell, which has acquired stem-like cell
properties. Thus, pCSCs is a paradoxical entity between normal
and cancer stem cells. On the one hand, they appear to be
uncommitted stem cells with incomplete multipotency; on the
other hand, they seem to be pre-determined, depending on
environmental cues, in the formation of solid or leukemic tumors.
This is not surprising because the contradictorial properties of
pCSCs reflect an important characteristic: their potential for
benign and malignant differentiation.
However, the biological definition for pCSCs remains open,
especially for its demarcation from CSCs [3]. Currently, human
Figure 6. Exclusive expression of piwil2 and embryonic stem cell-related genes in pCSCs. A, Exclusive expression of mili (piwil2) gene in pCSCs:
Total RNA was isolated randomly from 2C4, 3B5C and 3B6C cell cultures at various times or from the CD34
+Lin
2 and CD34
2Lin
2 BM cells of B6 mice,
which were purified by FACS Aria in 3 separate experiments, and was subject to RT-PCR analysis for embryonic, germ-line, and adult stem cell-related
stemness genes and oncogenic genes. The data represent at least 3 experiments. B, Inhibition of pCSC expansion in vitro by mili-specific siRNA: 2C4
cells (100 cells/well) were either transfected or not by mili-specific siRNA (100 nMol) or mock-transfected in triplicate in 24-well plates. The cells were
counted at indicated times. The data represent 5 experiments. **, p,0.01 as compared to the mock- or non-transfected groups. C, Knockdown of mili
mRNA by mili-specific siRNA: 2C4 cells (1610
6/well) were transfected by mili-siRNA or scramble nucleotide (nt) RNA, and harvested 48 hrs post
transfection. The expression of mili mRNA was revealed by RT-PCR. The data represent 3 experiments.
doi:10.1371/journal.pone.0000293.g006
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reconstitute cancer in immunodeficient mice [4,5,7]. It is not clear
whether these CSCs could reconstitute cancers in the immuno-
competent hosts. It is possible that these cells might be at the early
stage of CSC development. At present, the hypothesis, however, is
impossible to be tested in immunocompetent animals with human
pCSCs. Animal cancer models can precisely define the stages of
CSC development. It is commonly understood that some rodent
cancer cell lines cannot reconstitute cancers when transplanted
into immunocompetent hosts. These lines might have the
properties of pCSCs, as we have described in this study.
In fact, the existence of pCSCs has been implicated in human
LSCs. In the human acute myelogenous leukemia (AML), the
frequency of LSCs is extremely low and is approximately 0.1,1
per million AML blasts [4]. By tracking individual human LSCs in
NOD/SCID mice serially transplanted with AML cells, LSCs
were found not to be functionally homogeneous but, like the
normal HSC compartment, comprise distinct hierarchically
arranged LSC classes [55]. In this experimental model, two
important features for LSCs/CSCs were revealed: 1) some LSCs
are either quiescent or divide rarely and undergo self-renewal
rather than commitment after cell division; and 2) normal
developmental processes are not completely abolished during
leukemogenesis [55], This probably reflect a precancerous stage of
LSC/CSC development [4,55], although it is not clear whether
these cells, like pCSCs defined herein, have the potential for
benign differentiation. In non-hematopoietic tumors, pCSCs may
be responsible for the reversible precancerous lesions, such as
metaplasia and dysplasia, in tumor pathology [10], although the
notion remains to be substantiated.
The fate of pCSCs is determined by environmental cues. Our
studies indicate that pCSCs can differentiate into benign cells in
immunocompetent (IC) mice; or progress to cancer in SCID mice.
This does not mean that pCSCs do not have the potential to
progress to cancer in immunocompetent mice, or the potential to
differentiate into benign cells in the SCID mice. The notion is
supported by the fact that the pCSC-derived benign hepatoid cells
were detected in the same liver of SCID mice with metastatic
cancer. In the immunocompetent mice, the pCSC-derived
malignant cells may be eliminated by the mechanisms of
immunoediting. The benignly differentiated cells may not
necessarily be ‘‘normal’’, because they may still be genetically
Figure 7. Ectopic expression of mili in BM cells promotes cell proliferation. A. Schematic construct of Lenti-GFP-Mili viral vector. B, The effect of
ectopic expression of mili on marrow cell proliferation: BM cells from B6 mice were transduced with Lenti-GFP-Mili or Lenti-GFP viruses in 24-well
plates (n=4 well/group), as described in Methods. The number of GFP
+ colonies were counted at indicated times. **, p,0.01, compared to Lenti-GFP
group. C, Representative eGFP
+ EB-like colonies at day 10 post transduction (arrow). The micrographs were taken under the inverted fluorescent
microscope (Nikon, TE2000-U, Japan), using original magnification: 6200.
doi:10.1371/journal.pone.0000293.g007
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controllable in cell cycling, and thus are not malignant. In
addition, these genetically defective cells may be susceptible to
DICD or abortive differentiation, and only a few of them are alive
and detectable. This scenario may explain the low engraftment of
benign cells in the immunocompetent mice and blastocyst chimera
mice. Thus, the benign differentiation of pCSCs signifies that the
progeny of pCSCs may be eliminated by DICD and immunoedit-
ing, or sustained silent in an appropriate cue. In contrast, the
malignant differentiation implicates the enhanced, uncontrollable
cell survival and proliferation as well as resistance to DICD. This
may be true because we have found that CSCs are more resistant
to DICD than pCSCs upon stimulation by differentiating factors
(our unpublished data). The notion is also supported in part by the
fact that vaccination with pCSCs led to the resistance of hosts to
the challenge by tumorigenic cancer cells (unpublished observa-
tion). The undifferentiated pCSCs may be restricted in expansion
in vivo due to their clonal property, similarly to human LSC clones
[4]. The low engraftment of a single clone also suggests
a mechanism underlying the maintenance of homeostasis of
pCSCs, namely programmed silencing, which is warranted for
further investigation.
The pCSC-derived cells appear to be tissue-specific because
each eGFP-expressing cell overlapped morphologically with the
given tissue cells revealed by histology. Thus, we proposed that the
pCSCs, like other BM-derived CSCs [6], have the potential of
transdifferentiation, although we could not exclude the possibility
of cell fusion between pCSCs and relevant tissue cells [56]. The
benign transdifferentiation or the putative cell fusion probably
provides one of the mechanisms preventing pCSC progressing to
malignant cells.
The discovery of the potential of pCSCs for both benign and
malignant differentiation helps explain the complex process of
cancer development. Our studies suggest that the fate of
developing pCSCs is determined by the status of the host immune
system and the environmental cues (the site of cell colonization or
route of inoculation). The pCSCs appear to be scrutinized by the
mechanism of tumor immune surveillance [29] because the pCSC
clones 2C4, 3B5C and 3B6C, which have an identical phenotype
and karyotype, had different fates in three animal models with
different levels of immune surveillance (Supplementary Table S1).
They developed into neither solid nor leukemic tumors in native
immunocompetent mice when injected s.c., i.p., or i.v. However,
they developed into tumors (2C4 and 3B5C) or leukemia (3B6C) in
the NK cell-sufficient but T and B cell-deficient SCID mice with
a variable latency of tumor initiation and tumor incidence in
separate experiments. Interestingly, while all the pCSC clones did
not develop into chronic leukemia when injected i.v. into the
lethally irradiated, BM-reconstituted mice with defective but
recovering immune systems, they differentiated into non-malig-
nant cells in the regenerative area of tissues. However, the pCSC-
derived non-malignant cells might be able to re-dedifferentiate
into pCSCs or CSCs in tumorigenic environments, leading to
tumorigenesis (Fig. 8b). In addition, the pCSCs retained the
Figure 8. The developmental relationship between pCSC, CSC and cancer. A, Biological comparison between NSCs, pCSCs, and CSCs. B, Schematic
model of pCSC development: piwil2 might play an important role in pCSC development.
doi:10.1371/journal.pone.0000293.g008
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term repopulating activity. The long-term repopulation of pCSCs
or pCSC-derived cells in various organs of the BM-reconstituted
mice suggests that the immune system may not directly eliminate
the quiescent pCSCs; rather, it may recognize pCSCs either
undergoing DICD or developing to CSCs and eliminate them
quickly. As a consequence, the quiescent pCSCs can be
maintained in a limited clonal size. Thus, the fate of pCSCs is
associated with the levels of tumor immune editing in the host
[29]. Further analysis of pCSCs destiny, by regulating the level of
immune editing, will help identify the mechanisms underlying the
development and control of pCSC or CSCs.
In addition to tumor immune surveillance, pCSCs may also be
checked by differentiation-induced cell death (DICD). Transient
detection of pCSC-derived hematopoietic cells in the peripheral
blood of the BM-reconstituted recipients suggests that the
differentiating cells are short-lived and may spontaneously
undergo apoptosis. To support this, the pCSCs underwent
apoptosis when their incompletely abolished hematopoietic
differentiation programs were activated by lineage-specific cyto-
kines, such as G-CSF, GM-CSF, IL-7 and IL-15. Thus, DICD
may prevent pCSCs from progressing to CSCs. Taken together,
the fate of pCSCs is highly diversified and includes, depending on
environmental cues, programmed silence, DICD, benign in-
complete differentiation, elimination by immunoediting, and
progression to cancer.
Because cancer can be caused by hierarchically genetic and
epigenetic alterations [34,54], it is difficult to define a common
phenotype or genetic markers of CSCs with regard to their
stemness and tissue origin [3]. In support of this notion, we
demonstrated that the progression of pCSCs to cancer was
accompanied by the up-regulation of c-kit and Sca-1, as well as by
stable lineage markers, and increased genetic alterations. It would
be difficult to phenotypically distinguish pCSCs from CSCs if not
functionally. Further dissecting the developmental stages based on
these markers and genetic alterations may lead to phenotypically
distinguishing pCSCs from CSCs.
Genetically, it has also been difficult to define a gene marker for
CSCs because the oncogenic genes expressed in CSCs are
overlapped with those expressed in normal adult stem cells, such
as such as Bmi-1 [35]. We found, however, that pCSCs exclusively
expressed embryonic stem cell (ESC)-related stemness genes,
including POUF1/Oct-4 [39], TDGF1/Cripto [40], and Zfp42/
REX1 [41], though the significance is not clear. It is possible that
these genes confer pCSCs the multipotency of differentiation or
the capability of benign differentiation. Although these genes were
ambiguously expressed in pCSCs, they were undetectable in a CSC
line established in our laboratory (Li et al., unpublished),
suggesting that they may be subverted at the early stage of CSC
development. Moreover, piwil2 (alias mili in mouse or hili in
humans), a member of PIWI/AGO gene family [16], which is
exclusively expressed in testis and essential for stem cell self-
renewal in drosophila [16], gametogenesis [15], and small RNA-
mediated gene silencing [57], was stably expressed in pCSCs. The
piwil2 was also detected in various tumor cell lines of human and
animals with variable levels [unpublished observation & [52]],
probably related to the number of pCSCs and/or CSCs in each
line. It is likely that ectopic expression of piwil2 may contribute to
the development of pCSCs and CSCs (Fig. 8b) because the
knocking-down of piwil2 mRNA led to the contained pCSC
proliferation in vitro. Consistently, overexpression of piwil2 in BM
cells led to enhanced proliferation in vitro. These results are
consistent with the recent observation from the piwil2-over-
expressing NIH3T3 cell line [52], suggesting that the piwil2 effects
on pCSC development. However, the function of piwil2 is complex
than we imaged, for it may regulate large numbers of piwi-
interacting RNA (piRNA) [58,59]. Unexpectedly, the piwil2 was
not required for the self-renewal of HSCs, because the number
and repopulation activity of hematopoietic stem cells from the BM
of mili-disrupted mice was not affected [15]. Although the pCSC
clones were derived from a p53
2/2Stat-1
2/2 mouse [14], p53 and
Stat-1 has no direct effect on piwil2 expression. Thus, the roles of
ectopic expression of piwil2 in pCSC development in vivo need
further exploration.
It would be ideal to characterize the freshly isolated pCSCs
from fresh tumor tissues at a single-cell level to avoid any possible
results of due to cultural artifact. However, this is technically
difficult because only exist rare numbers of pCSCs in tumors.
Moreover, it is difficult to isolate a single pCSC based on its
phenotype because pCSCs may be phenotypically heterogeneous
due to their hierarchical or multiple genetic alterations. To prove
the existence of pCSCs, we performed ex vivo limiting dilution at
the beginning of our experiments [14] and obtained three pCSC
clones with an identical karyotype. Thus, the data obtained from
these pCSC clones appear to be at a single-cell level. It would be
possible to further show the benign and malignant differentiation
of these clonal pCSCs at a single-cell level. However, it was also
difficult, and it may be related to the unique properties of
differentiating pCSCs, such as their DICD, susceptibility to
immunoediting, and programmed silencing. Even for CSCs, their
existence has not been demonstrated at a single-cell level [4–9].
However, this does not exclude the existence of CSCs. Moreover,
normal tissue stem cells, such as mammary epithelial stem cells,
and their outgrowth at a single-cell level can be demonstrated in
only one of several hundred transplants [60]. To further prove that
pCSCs have the potential for benign and malignant differentia-
tion, we performed blastocyst complementary experiments with
only a few clonal pCSCs and verified the potency of benign
differentiation of pCSCs in the blastocyst chimera. Moreover, the
altered karyotype of pCSC-derived tumor cells, though nearly the
same as parent cells, also suggests that pCSCs can progress to
cancer.
Overall, we have experimentally identified and characterized
the pCSCs, which may be important for understanding the
mechanism underlying CSC development. Our findings provide
the first evidence that single-cell pCSCs clones have the potential
for both benign and malignant differentiation, depending on
environmental cues. A broad therapeutic approach to the cure of
various types of cancers may be achievable through rational
targeting of pCSCs.
METHODS
Experimental procedures
Mice, cell lines, and reagents C57BL/c (B6) and SCID CB17
mice were used at the age of 8–12 wk. The mice were bred and
maintained in the animal pathogen-free facility at The Ohio State
University Medical Center. Cell lines 2C4, 3B5C and 3B6C were
cloned from a mouse with dendritic cell-like leukemia, as
previously described [14]. All mAbs and cytokines were
purchased from, respectively, BD PharMingen and PeproTech,
except where indicated.
Cell culture The cell lines were maintained in R10F (RPMI
1640 plus 10% fetal calf serum supplemented with 5 mM
glutamine, 50 mM 2-mecaptoethonal, 100 U/ml penicillin, and
100 mg/ml streptomycin) [14]. In some experiments, the cells were
cultured in the presence or absence of cytokines, including the
supernatant of G-CSF secreting U87MG cell culture [61],
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the log phase of cell growth to prevent over population-induced
cell death. The cytology was examined at various time points by
Giemsa-staining of cytospin preparations, or directly monitored
under a phase contrast microscope.
Purification of BM marrow stem cells Lin
2CD34
+ and
Lin
2CD34
2 BM cells were purified from B6 mice using MACS
beads followed by FACS sorting. Briefly, BM cells were isolated
and stained with a cocktail of biotinylated mAbs to lineage (Lin)
markers CD3e, CD11b, B220, Gr-1, and Ter-119, and then
incubated with MACS beads coated with mAb to biotin (Miltenyi,
Biotech Inc.). Lin
2 cells were negatively selected, as instructed by
the manufacturer (Miltenyi Biotech Inc.), stained with mAb to
FITC-conjugated CD34 and PerCP-Cy5-conjugated streptavidin,
and sorted for Lin
2CD34
+ and Lin
2CD34
2 populations using
FACS Aria (BD Science). The purity of each population was
.98%.
Generation of eGFP
+ cell lines To track the fate of pCSCs in
vivo, 2C4 cells were transduced with pseudo-lentiviruses carrying an
enhanced green fluorescent protein (eGFP) gene and a blasticidin-
resistant gene. The eGFP
+ cells were cloned by limiting dilution
and maintained in R10F for more than 2 months. Flow cytometry
was used to determine the clones that stably expressed eGFP. A
clone, 2C4G2, which expressed the appropriate fluorescent
intensity of eGFP was used for experiments, and parent 2C4 cells
were used as a control.
Hematopoietic CFU assay Mouse clonogenic hematopoietic
progenitor assays were performed to assess the capacity of
multilineage differentiation by pCSCs. pCSCs were plated into
MethoCult GF M3434 (StemCell Technologies), and colonies
(.50 cells) were scored after 12,14 d incubation at 37uC and 5%
CO2, as instructed by manufacturer.
In vivo competitive repopulating assay pCSCs or eGFP
+
pCSCs (0.5,10610
5) were injected into the tail vein of lethally
irradiated (900 rad) CD45.1 congenic B6 mice, along with or
without 2,5610
5 host-type BM cells. Donor-derived CD45.2 cells
from peripheral blood were assessed by flow cytometric analysis
for lymphoid (CD3
+) and myeloid (CD11b
+ and Gr-1
+) cells every
2 wks, starting at 4 wks and ending 20 wks after transplant. Then
the mice were maintained and sacrificed 5 or 10 months after
transplant. Peripheral blood, BM, and various organs were
harvested and examined, using HANDS-Nested DNA PCR, to
determine if the neo
r gene had integrated in the genome of donor
cells.
Secondary repopulation assay The BM cells (1610
6),
isolated from primary recipient mice 10 months after transplant,
were injected i.v. into lethally irradiated CD45.1 congenic B6
mice. The secondary recipients were sacrificed 5 moths after
transplant. Donor-specific cells in the blood, BM, and liver were
determined for the neo
r gene using HANDS-Nested DNA PCR.
Tumorigenesis assay SCID CB17 mice were injected i.p.,
s.c., or i.v. with 5610
6 pCSCs. Tumor incidence and size were
monitored once every other day starting 1 wk after inoculation.
The group was sacrificed when one of the mice developed a tumor
more than 15,20 mm in diameter. Tumors and various organs
were harvested for histological analysis, immunochemical staining,
and/or flow cytometric analysis.
Generation and characterization of blastocyst chimera
mice Four-week old FVB/N female mice (Taconic Farm) were
superovulated by subcutaneous injection of 5 IU of Pregnant
Mare’s Serum (PMSG, NHPP) followed 46–48 h later with 5 IU
of Human Chorionic Gonadotropin (hCG, Sigma). Females were
subsequently mated with FVB/N stud male mice. Embryos were
flushed from the uterine horn of the female mice (3.5 dpc) and
then sacrificed. Blastocysts were collected and maintained in
HEPES buffered CZB [62] during microinjection.
Microinjection was similar to injecting embryonic stem cells into
blastocysts [62]. The Peizo-Micromanipulator [63] was used to
inject 2C4G2 or 2C4 pCSCs. The injection pipette was prepared
to the inner diameter 10,15 mm with Narishige Microforge.
Approximately 8,10 cells were injected into fully expanded
3.5 dpc blastocysts. The injected blastocysts were incubated in
CZB culturing medium [62] at 37uC, 5% CO2 incubator for
30 minutes and then surgically transferred to the oviduct of
0.5 dpc pseudopregnant ICR mice. Adult progeny was charac-
terized for eGFP
+ red blood cells (RBC) in peripheral blood under
fluorescent microscope, CD45
+eGFP
+ white blood cells (WBC) by
flow cytometry, and eGFP signals (photon counts) in the living
body by IVIS imaging system 100 Series (Xenogen Inc.).
RT-PCR Total RNA was extracted from cell lines or de novo
isolated HSCs. The cDNA was generated by reverse transcription
using Superscriptase II (Invitrogen, CA) and oligo (dT) in a 20 ml
reaction containing 1 mg of total RNA, which was pretreated with
RNase-free DNase I (Invitrogen, CA) to eliminate contaminating
genomic DNA. Briefly, an aliquot of 0.5 ml cDNA was used in
each 20 ml PCR reaction, using PCR Master Mix (Promega, Ca).
The following conditions were used: an initial denaturation at
95uC for 5 min followed by denaturation at 94uC for 30 seconds,
annealing at 65uC for 1 min, touchdown 21uC per cycle, and
extension at 72uC for 1 min for a total of 10 cycles. Then the
condition was fixed for 25 cycles of denaturation at 94uC for
30 seconds, annealing at 50uC for 1 min, and extension at 72uC
for 1 min with a final extension at 72uC for 10 min. PCR products
were analyzed by 1.5% agarose gel. The sequence of primers is
listed in supplementary Table S2.
Genomic DNA isolation Genomic DNAs of all tissues except
blood were isolated following overnight digestion with 500 mlo f
DNA lysing buffer (100 mM NaCl, 10 mM Tris-HCl, 25 mM
EDTA, 1%SDS, and 50 mg/ml proteinase K) at 56uC. The
supernatant (400–450 ml) was transferred to a new 1.5 ml tube
after 10 min centrifugation at 13,200 RPM, and genomic DNA
was extracted using a silica-gel method. For blood samples red
blood cells were removed with ACK lysing buffer (NH4Cl 8.29 g/
L, KHCO3 1.00 g/L, EDTA 0.037 g/L, pH 7.4) before digestion
with DNA lysing buffer.
HANDS-Nested DNA PCR HANDS-Nested DNA PCR,
a technique that combines HANDS (Homo-Tag Assisted Non-
Dimer System) PCR [25,26] with Nested PCR [27], was used to
reduce primer-dimer formation and amplify genes of low copy
numbers. The genomic neo
r gene was first amplified using
HANDS-PCR followed by Nested-PCR. The primary PCR was
performed for 45 cycles followed by 25 cycles of secondary PCR
with the primary PCR product as templates in a 1:2500 dilution
(final). All reactions are in a 20 ml of volume. In the primary
HANDS-PCR two hybrid primers and one Tag primer were used:
59-CGTACTAGCGTACCACGTGTCGACTATTCGGCTA-
TGACTGGGCACAACA -39(T1-Neo-forward) at 0.02 mM, 59-
GCGTACTAGCGTACCACGTGTCGACTGTCAAGAAGG-
CGATAGAAGGCGAT-39(T1-Neo-reverse) at 0.02 mM, and
59-GCGTACTAGCGTACCACGTGTCGACT-39 (T1) at
0.25 mM. The following touchdown thermal conditions were
used : 95uC for 5 min, 5 cycles of 94uC for 30 s, 70uC for 1 min,
touchdown 21uC/cycle, and 72uC for 1 min; 5 cycles of 94uC for
30 s, 68uC for 1 min, touchdown 21uC/cycle, and 72uC for
1 min; 35 cycles of 94uC for 30 s, 60uC for 1 min, and 72uC for
1 min; 72uC for 15 min at the final extension. The expected size of
amplicon was 792bp. The primary PCR products were diluted
with 16Tris buffer (pH 8.0) and used as templates (1:1250, final)
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AGGACGAGGCA-39 (forward, 0.25 mM) and 59-GGGTAGC-
CAACGCTATGTCCTGATA-39 (reverse, 0.25 mM). The PCR
conditions were: 95uC for 5 min, 10 cycles of 94uC for 30 s, 65uC
for 1 min, touchdown 21uC/cycle, 15 cycles of 94uC for 30 s,
50uC for 1 min, and 72uC for 1 min; 72uC for 10 min at the final
extension step. All the nested-PCR products were separated on
a 1.5% agarose gel at the 5 v/cm for 60 min. The expected PCR
products were 507 bp. House-keeping gene 18SrRNA
(Supplementary Table S2) was amplified using the primary PCR
thermal conditions, and 10 ml were loaded as an internal loading
control. PCR Master Mix (Promega, Cat No. M7502) was used in
all the reactions.
RNA interference pCSCs cells were transfected with mili-
specific small interference (si) RNA (UCGUACCUACCGAA-
UCGAU) or scramble siRNA (CACGUGAGGAUCACCAUCA)
using an siRNA transfection kit, as instructed by the manufacturer
(Qiagen). For the effect of mili siRNA on cell expansion, a low
density of transfected cells (100/well) were seeded and counted at
indicated times. For RT-PCR analysis of mili gene expression,
a high density of transfected cells (1610
6/well) were seeded and
harvested at 48 hrs of culture.
Construction of lentiviral GFP-Mili vectors To construct
the mili lentiviral expression vector, two primers, under the control
of CMV promoter, were used to amplify the cDNA coding for mili
gene by PCR: 59 - GATTCGGAATTCACAACCAT GGATCC-
TGTCAGGCCGTTGTTCA - 39 and 59–TTAACGTGAATT-
CTTACAGG AAGAACAGGTTCCCACACAGCTG - 39. The
full-size of mili cDNA in plasmid pcDNA-FLAG (a gift from Dr.
Nakano, Osaka University, Japan) was used as the template [15].
The synthesized mili cDNA from PCR, which has an EcoRI site in
both ends derived from primers, was cloned into the lentiviral
vector pLenti6-ZsGreen (Fig. 7a), which is derived from a recom-
bination of the Zoanthus sp. green fluorescent protein (ZsGreen)
(Clontech) and pLenti6/V5-TOPO (Invitrogen), at the EcoRI site
to produce pLenti6-ZsGreen-Mili. The insert of mili was verified
by sequencing. Pseudotype pLenti6-ZsGreen-Mili (Lenti-GFP-
Mili) and pLenti6-ZsGreen viruses (Lenti-GFP) were produced by
transfecting the 293FT cell line, as instructed by manufacturer
(Invitrogen). The viral supernatants were harvested on 72 hr post
transfection.
Transduction of BM cells The BM cells, isolated from
femoral and tibia bones of B6 mice, were transduced with Lenti-
GFP-Mili or Lenti-GFP viruses. Briefly, BM cells (1610
6)w e r e
incubated with 0.3 ml viral supernatant at 37uCf o r3 0 ,60 min.
Then 0.7 ml serum-free medium HBCM-2 containing 5%
XLCM
TM [53,64], which can expand hematopoietic progenitor
cells (our unpublished data), were added into the cultures. The GFP
+
colonies were counted as an indicator of BM cell proliferation.
Karyotype analysis Exponentially growing cells were fixed
using standard laboratory procedures. The cell suspension was
dropped onto pre-cleaned, warm, wet, slides. The slides were aged
at 90u C for 1 hour, banded with trypsin, and stained with Wright
stain. Banded metaphases were analyzed using a Zeiss Axioskop
40. For each cell line, 10 metaphases were karyotyped using an
Applied Imaging Karyotyping System.
To monitor genetic alterations of the pCSCs progressing to
cancer, 2C4, 3B5C, 3B6C cells (5610
6) were injected s.c. into
SCID mice, and the resultant tumors were harvested and single
cells were prepared. The single cells were cultured in vitro until they
grew sufficiently for karyotype analysis.
Flow cytometry Single cells prepared from blood and tumors
were stained with corresponding mAbs and then analyzed by flow
cytometry, as described previously [14].
Histology The tumors and tissue samples were fixed in
formalin and embedded in paraffin for pathological and
immunohistochemical analysis. Sections were stained by H. & E.
for pathological analysis. To identify neomycin in tissues, the
sections were immunostained with a polyclonal rabbit anti-
neomycin (Upstate Cell Signaling Solutions, Lake Placid, NY)
and followed by a horseradish peroxidase-conjugated goat anti-
rabbit IgG. Sections were counterstained with haematoxylin.
Statistical analysis Multiple groups of observations were
analyzed by the one-way analysis of variance (ANOVA), and two
groups of observations were compared by student-T test. A value
of p#0.05 was considered significant. Data are represented as
mean6SD. *, p#0.05; **, p#0.01.
SUPPORTING INFORMATION
Figure S1 Incomplete differentiation of pCSCs in the CFC
assay. The cells (2C4, 3B5C or 3B6C) were plated (100 or
200 cells/well) in semisolid methylcellulose medium of Metho-
CultTM GF M3434 (StemCell Technologies Inc. Canada) for
CFC assay. The colonies were counted 2 wks after culture (A & B).
The lineage-specific gene expression was analyzed by RT-PCR
before or at day 11 of culture, and the BM cells were used as
a positive control (C). The experiments were repeated 3 times with
similar results. The data shown in A are expressed as mean6SD.
Found at: doi:10.1371/journal.pone.0000293.s001 (0.20 MB TIF)
Figure S2 The effect of cytokines on pCSC differentiation in
vitro. A & B, The effect of G-CSF on pCSC differentiation: The
cells (75,000/flask) of 2C4, 3B5C and 3B6C clones were cultured
in 10 ml R10F medium containing 10% of G-CSF-supernatant.
Starting from d 5 of culture, the medium was replenished every
other day with 30 ml of medium containing 10% of G-CSF
supernatant. The viable cells were counted every other day until
all of them died (A). The cytological alterations of the pCSCs were
monitored by Wright-Giemsa staining at each time point. The
micrographs (B) show a representative from the clone 3B6C of
three experiments. Control cultures in the absence of G-CSF
supernatant did not cause cell death (data not shown). C, The
effect of GM-CSF on pCSC differentiation: 2C4 cells were
cultured (100 cells/well) in R10F containing 5 ng/ml recombinant
murine GM-CSF (PeproTech, Inc, Rocky Hill, NJ) in 24-well
plates. The data shown are representative from the cultures in the
absence (left panel) or presence of GM-CSF (right panel) of three
experiments. D & E, The effect of IL-7 and IL-15 on pCSC
differentiation: 2C4 cells (100/well) were cultured in the presence
of IL-7 (50 ng/ml) or IL-15 (50 ng/ml) or in a combination of
them. The cells were harvested on days 9 and 12 of culture and
either stained with mAbs to NK1.1 and B220 (D) or cytospined for
Wright-Giemsa staining (E). The data represent three experi-
ments.
Found at: doi:10.1371/journal.pone.0000293.s002 (0.48 MB TIF)
Figure S3 pCSCs can repopulate in various organs of recipients.
2C4 cells (5610
5) were transplanted into lethally irradiated
CD45.1 B6 mice, along with 2610
5 recipient-type BM cells.
The mice were sacrificed 5 month latter, and various organs were
harvested for analysis of pCSC-derived neor gene, using HANDS-
Nested DNA PCR. The data were from one of 3 experiments. The
organs from control (ctrl) mice were used as the negative control,
and 2C4 and 2C4G2 cell lines were used as positive controls.
Found at: doi:10.1371/journal.pone.0000293.s003 (0.31 MB TIF)
Figure S4 Generation of stable eGFP expressing cell lines. 2C4
cells were transduced with Lenti-GFP viral vectors and selected in
the presence of puromycin for .2 months. The drug-resistant cells
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+ clones were identified
by flow cytometry. The histogram depicted the fluorescent
intensity of a representative clone 2C4G2, which was used
throughout the experiments.
Found at: doi:10.1371/journal.pone.0000293.s004 (0.05 MB TIF)
Figure S5 pCSC-derived metastatic tumors in various organs.
A, metastatic tumor in the spleen, liver, pancreas and prostates.
The data represent tissues derived from the mice injected with
2C4 (spleen and liver) or 3B5C (pancreas and prostate). Original
magnification: 6400.
Found at: doi:10.1371/journal.pone.0000293.s005 (1.64 MB TIF)
Figure S6 Restrained tumorigenesis of pCSCs after intravenous
inoculation. SCID mice were injected i.v. with 5610
5 2C4, 3B5C
or 3B6C (n=3/group). As a control, the lethally irradiated B6
mice were injected i.v. with the same number of 2C4, 3B5C or
3B6C cells (n=4/group) together with 5610
5 recipient-type BM
cells. The mice were sacrificed 5 months later, and various organs
or tissues, including the spleen, liver, kidney, lungs, intestines,
pancreas and blood, were harvested from the SICD and BM-
reconstituted B6 mice for pathological examination. None of the
organs developed cancer, except for the spleens of SCID mice. A,
The structure of normal spleen of SCID mice; B, The leukemic
alteration in the spleen of SCID mice injected i.v. with pCSCs: the
micrograph shown is from a mouse injected i.v. with 36BC cells;
C, Blast cells detected in the blood smears: a representative from
a SCID mouse injected with 2C4 cells; D, Normal appearance of
the spleens from the BM-reconstituted mice: the micrograph
shows a representative from a mouse injected with pCSCs (2C4
clone). Original magnification for H& E. staining sections: 6400;
blood smear: 61000. The insets are enlargements indicated by
arrows.
Found at: doi:10.1371/journal.pone.0000293.s006 (1.29 MB TIF)
Table S1 Effect of environments on the tumorigenesis of pCSCs
Found at: doi:10.1371/journal.pone.0000293.s007 (0.04 MB
DOC)
Table S2 Primer sequence used for RT-PCR
Found at: doi:10.1371/journal.pone.0000293.s008 (0.13 MB
DOC)
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